BHC jumps 11% as Solta Medical acquires Wuhan Shibo Zhenmei, gaining full control of its China aesthetics distribution business.
Bausch Health Companies Inc. (BHC) Presents at Evercore 8th Annual Healthcare Conference Transcript
Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
| Specialty Retail Industry | Consumer Discretionary Sector | Thomas J. Appio CEO | TSX Exchange | CA0717341071 ISIN |
| CA Country | 20,700 Employees | 11 Jun 2014 Last Dividend | 16 Oct 2000 Last Split | - IPO Date |
Bausch Health Companies Inc. is a global player in the specialized pharmaceutical and medical device sector, with operations spanning both the United States and numerous other countries around the world. Its focus areas include gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. Originally known as Valeant Pharmaceuticals International, Inc., the company underwent a name change in July 2018, marking a new chapter in its history. Headquartered in Laval, Canada, the organization functions through five key segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb, each targeting specific market needs.
Bausch Health's diverse portfolio extends across various medical domains, including: